Page 6,759«..1020..6,7586,7596,7606,761..6,7706,780..»

England National Institute for Health Research Stroke Research Network Adopts Gore REDUCE Clinical Study

Posted: Published on June 19th, 2012

NEWCASTLE, England & FLAGSTAFF, Ariz.--(BUSINESSWIRE)-- W. L. Gore & Associates (Gore) today announced that the National Institute for Health Research Stroke Research Network has adopted the Gore REDUCE Clinical Study to help drive patient recruitment across England. The Gore REDUCE Clinical Study is designed to demonstrate that Patent Foramen Ovale (PFO) closure with the GORE Septal Occluder plus antiplatelet medical management reduces the risk of recurrent stroke or imaging-confirmed transient ischemic attack (TIA) when compared to antiplatelet medical management alone in patients with a PFO and history of cryptogenic stroke or imaging-confirmed TIA. The prospective, randomized, multi-center, multi-national trial will include up to eighty investigational sites in the US, Europe and Canada. The National Institute for Health Research Stroke Research Network supports vital stroke studies such as the Gore REDUCE Clinical Study by providing coordination, leadership and practical help. It supports both academic research and industry-sponsored studies, offering 100 percent coverage of the National Health Service hospitals nationwide. Established in 2006, the network has increased patient recruitment six-fold. It also provides a patient and career involvement program that aims to make a real impact on both the quality and delivery of stroke research. PFO closure is known as a low-risk … Continue reading →

Comments Off on England National Institute for Health Research Stroke Research Network Adopts Gore REDUCE Clinical Study

Dove Daily Treatment Conditioner review – Platinum Ms – Video

Posted: Published on June 19th, 2012

18-06-2012 00:51 Watch on above and read the reviews below to see what our Trial Teamers thought after road-testing this treatment conditioner... Find out more: Originally posted here: Dove Daily Treatment Conditioner review - Platinum Ms - Video … Continue reading →

Posted in MS Treatment | Comments Off on Dove Daily Treatment Conditioner review – Platinum Ms – Video

Jack Osbourne Diagnosed With Multiple Sclerosis: What Symptoms And Treatment Await Ozzy's Son?

Posted: Published on June 19th, 2012

Jack Osbourne, reality TV star and son of rock god Ozzy Osbourne, told People magazine that he has been diagnosed with multiple sclerosis. The long-term outlook for Osbourne's health, however, apparently is not nearly as dire as the news might suggest. Treatment for symptoms is available that could allow Osbourne to lead a full life with few complications, despite MS, some doctors say. "I was just angry and frustrated and kept thinking, 'Why now?'" Osbourne, 26, said. "I've got a family and that's what's supposed to be the most important thing." The news came two weeks after his fiance Lisa Stelly gave birth to their daughter Pearl Clementine. Osbourne said he noticed that he lost most of his vision in his right eye. "The timing was so bad", Jack told HELLO! Magainze. "I'd just had a baby, work was going great ... I kept thinking: 'Why now?'" Follow us Multiple sclerosis is an autoimmune disease that attacks the central nervous system, which has no known cure. Its symptoms include difficulties in vision, loss of muscle control, balance and in severe cases, paralysis. It is usually diagnosed in people in their 20s, and 30s. There are 200 new cases of MS … Continue reading →

Posted in MS Treatment | Comments Off on Jack Osbourne Diagnosed With Multiple Sclerosis: What Symptoms And Treatment Await Ozzy's Son?

Innate Immunotherapeutics’ MS drug to go to second trial

Posted: Published on June 19th, 2012

Innate Immunotherapeutics MS drug to go to second trial Auckland, NZ, June 19 2012: New Zealand biopharmaceutical company Innate Immunotherapeutics says trials of its drug to help people with chronic, progressive multiple sclerosis (MS) are showing positive results. Simon Wilkinson, chief executive of Innate Immunotherapeutics, says results of the Phase 1/2 clinical trial have shown MIS416 to be well tolerated and identified a clinical dose for further evaluation. MIS416 is the lead product from the Auckland-based biopharmas proprietary immune modulating microparticle technology. Neurologist Professor Tim Anderson, co-principal investigator for the study, says the preliminary data indicate that MIS416 was safe and well tolerated. The MS-related clinical status assessment tools used during the study also indicate that the trial agent may have had some positive effect for many of the treated patients. During the dose confirmation portion of the study, eight of 10 patients with secondary progressive MS treated with MIS416 for 12 weeks showed some improvement in their MS-related signs and symptoms. For example, 50% of the study subjects showed some improvement in EDSS scores over the relatively short 12 week duration of the trial, Professor Anderson says. These interim results are encouraging and merit the consideration of a randomised, … Continue reading →

Posted in MS Treatment | Comments Off on Innate Immunotherapeutics’ MS drug to go to second trial

For A Cure Foundation’s stem cell radio ad wins Siren Award

Posted: Published on June 19th, 2012

Cancer charity For A Cure Foundations radio ad promoting stem cell research has won this months round of the radio industrys 2013 Siren Awards, organised by Commercial Radio Australia. The ad promoting stem cell research for the For A Cure Foundation has won the overall and singlecategories in round one of the 2013 Siren Awards. JayGrey Sydney creative team Gav Chimes and Tommy Cehak created the ad. The team said in a release, Its a powerful thing but theres little awareness about it. Theres a lot ofmisunderstanding when it comes to stem cell research. For this reason, the general public doesnt think ortalk about it, and remain largely unaware of the benefits. We wanted to wake people up by reframing theissue and focusing on the suffering that can be alleviated. Other finalists included a radio ad for Ikea called Gas Leak written by Tim Green andKaren Ferry of The Monkeys which picked up a Highly Commended award.SBS were awarded a Highly Commended for Bite Me Vietnam written byDavid Roberts and Tim Chenery from Sydney agency Us. The winner of the campaign category was Chocolatte/Mango/Cafe Au Lait for Bannister Downs Dairy Milk, created by production agency Writing by Steve Browning in … Continue reading →

Posted in Stem Cell Research | Comments Off on For A Cure Foundation’s stem cell radio ad wins Siren Award

State Awards $9.8 Million For Stem Cell Projects

Posted: Published on June 19th, 2012

Gov. Dannel P. Malloy Monday announced $9.8 million in grants to 19 stem cell research projects in the state. The Connecticut Stem Cell Research Advisory Committee had selected the recipients at its grant review meeting last Tuesday in Farmington. "Connecticut's continued support of stem cell research has allowed for exciting and innovative research to take place right here in our state," Malloy said in a statement. "The research projects funded by these grants allow scientists to do revolutionary work that puts Connecticut at the forefront of bioscience industry." Of the 19 grants, 13 grants totaling $7.25 million were awarded to Yale scientists, five went to University of Connecticut researchers, and one went to a collaboration between Wesleyan and UConn scientists. The largest grant, $1.8 million, was awarded to D. Eugene Redmond of Yale. Redmond has focused on cellular repair in the nervous system and how it relates to Parkinson's disease. UConn's Stormy Chamberlain, an assistant professor of genetics and developmental biology at the UConn Health Center, received a $450,000 grant to develop new therapies for Prader-Willi syndrome and Angelman Syndrome, both rare genetic disorders. Children born with Prader-Willi Syndrome have difficulty feeding and develop poor muscle tone, and starting about … Continue reading →

Posted in Stem Cell Research | Comments Off on State Awards $9.8 Million For Stem Cell Projects

Another Nod for Osiris' Prochymal – Analyst Blog

Posted: Published on June 19th, 2012

Referenced Stocks: OSIR, SNY Just a few weeks after gaining approval in Canada, Osiris Therapeutics, Inc.'s ( OSIR ) stem cell therapy, Prochymal, gained approval in New Zealand. Prochymal gained approval for the treatment of acute graft-vs-host disease (GvHD) in children. Osiris had submitted its marketing application to Medsafe, the medical regulatory agency in New Zealand, in May 2011. Prochymal was granted priority review status. Prochymal is the first manufactured stem cell product to gain approval and the first treatment to gain approval for GvHD. Besides being approved in Canada and New Zealand, we note that Prochymal is available under an Expanded Access Program (EAP) in seven countries including the US. Our Take Prochymal's approval in New Zealand is a boost for Osiris. Shares were up 13.75% on the news. Prochymal is the lead candidate at Osiris and represents significant commercial potential. Prochymal is currently being evaluated for other indications as well including refractory Crohn's disease (phase III), type I diabetes, and myocardial infarction (heart attack - phase II). We currently have low visibility on the status of Osiris' development and commercialization agreement with Genzyme, a Sanofi ( SNY ) company, for Prochymal. Earlier this year, Sanofi, in its fourth … Continue reading →

Comments Off on Another Nod for Osiris' Prochymal – Analyst Blog

Chicago woman cured of sickle cell disease

Posted: Published on June 19th, 2012

ScienceDaily (June 18, 2012) Chicagoan Ieshea Thomas is the first Midwest patient to receive a successful stem cell transplant to cure her sickle cell disease without chemotherapy in preparation for the transplant. University of Illinois Hospital & Health Sciences System physicians performed the procedure using medication to suppress her immune system and one small dose of total body radiation right before the transplant. The transplant technique is relatively uncommon and is a much more tolerable treatment for patients with aggressive sickle cell disease who often have underlying organ disease and other complications, says Dr. Damiano Rondelli, professor of medicine at UIC, who performed Thomas's transplant. The procedure initially allows a patient's own bone marrow to coexist with that of the donor. Since the patient's bone marrow is not completely destroyed by chemotherapy or radiation prior to transplant, part of the immune defense survives, lessening the risk of infection. The goal is for the transplanted stem cells to gradually take over the bone marrow's role to produce red blood cells -- normal, healthy ones. Thomas, 33, had her first sickle cell crisis when she was just 8 months old. Her disease became progressively worse as an adult, particularly after the birth … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Chicago woman cured of sickle cell disease

Stem Cell Therapy for CMT-Gary B-part 2.mp4 – Video

Posted: Published on June 19th, 2012

17-06-2012 23:59 Gary B Stem Cell Therapy for CMT Part 2 - For more info. visit More here: Stem Cell Therapy for CMT-Gary B-part 2.mp4 - Video … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Stem Cell Therapy for CMT-Gary B-part 2.mp4 – Video

Sistemic to Moderate Regenerative Medicine Panel at 2012 Bio International Convention

Posted: Published on June 19th, 2012

BOSTON--(BUSINESS WIRE)-- Sistemic Ltd., a leading provider of microRNA-based problem-solving services and kit-based products to the Cell Therapy community, announced today that chairman and CEO Jim Reid is moderating a panel discussion at the 2012 Bio International Convention on Wednesday, June 20, in Boston. Featuring leaders from the regenerative medicine space, the panel is titled Stem Cell Therapies Fact or Fiction, and will share the lessons learned to-date from Scottish, European and American perspectives on the path to successfulcommercialization of stem cell therapies. Jim Reid, Sistemic CEO, commented, "Sistemic is very active in the CellTherapyarena and aremembersof Alliance for Advanced Therapies (AAT) and the Alliance for Regenerative Medicine (ARM). We see the ability to raise this topic at the leading world event, BIO 2012, as animportantstep on the path to commercialization of these products which will be transformational in healthcare, and bring hope and cures to many people around the globe." More information on the panel at BIO 2012: What: Panel Discussion Featuring Leaders in the Regenerative Medicine Space When: Wednesday, June 20, 3:00PM EDT Where: Boston Convention Center, Room 254A Who: Leaders of the Regenerative Medicine space: Panel objectives include evaluating lessons learned and best practice including from the … Continue reading →

Posted in Mesenchymal Stem Cells | Comments Off on Sistemic to Moderate Regenerative Medicine Panel at 2012 Bio International Convention

Page 6,759«..1020..6,7586,7596,7606,761..6,7706,780..»